TF 0023
Alternative Names: TF-0023Latest Information Update: 06 Mar 2024
Price :
$50 *
At a glance
- Originator Techfields Pharma
- Class Antithrombotics; Small molecules
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Chronic heart failure; COVID 2019 infections; Myocardial infarction; Pulmonary embolism; Stroke
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 05 Mar 2024 Phase-II clinical trials in Chronic heart failure (unspecified route) (Techfields Pharma pipeline, March 2024)
- 05 Mar 2024 Phase-II clinical trials in Myocardial infarction (unspecified route) (Techfields Pharma pipeline, March 2024)
- 05 Mar 2024 Phase-II clinical trials in Pulmonary embolism (unspecified route) (Techfields Pharma pipeline, March 2024)